Analyst Price Targets — CRMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 28, 2026 11:41 am | Leonid Timashev | RBC Capital | $14.00 | $7.82 | TheFly | CorMedix price target raised to $14 from $13 at RBC Capital |
| March 6, 2026 8:13 pm | Roanna Ruiz | Leerink Partners | $13.00 | $6.46 | StreetInsider | CorMedix (CRMD) PT Lowered to $13 at Leerink Partners |
| January 23, 2026 11:08 am | — | H.C. Wainwright | $13.00 | $7.44 | TheFly | CorMedix price target lowered to $13 from $18 at H.C. Wainwright |
| January 21, 2026 11:34 am | — | RBC Capital | $13.00 | $6.88 | TheFly | CorMedix price target lowered to $13 from $22 at RBC Capital |
| January 8, 2026 5:42 pm | — | Truist Financial | $16.00 | $7.44 | TheFly | CorMedix price target lowered to $16 from $20 at Truist |
| October 21, 2025 11:08 am | Gregory Renza | RBC Capital | $22.00 | $12.16 | TheFly | CorMedix price target raised to $22 from $21 at RBC Capital |
| August 8, 2025 10:03 am | Brandon Folkes | H.C. Wainwright | $17.00 | $10.33 | TheFly | CorMedix price target lowered to $17 from $20 at H.C. Wainwright |
| March 13, 2024 6:21 am | Gregory Renza | RBC Capital | $9.00 | $3.90 | StreetInsider | CorMedix (CRMD) PT Lowered to $9 at RBC Capital |
Latest News for CRMD
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District of Illinois that the patents covering its product MINOCIN® for Injection are valid and infringed by the product developed by Nexus Pharmaceuticals, Inc.
CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF modeling. CRMD faces a 2027 revenue trough post-TDAPA, but I expect growth to reignite from 2027 to 2028, driven by DefenCath adoption and pipeline progress. Key mid-to-long-term catalysts include potential DaVita onboarding, federal market expansion, and pipeline assets like DefenCath TPN and REZZAYO.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRMD.
U.S. House Trading
No House trades found for CRMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.